Welcome: Guest | Site Use Options | Register | Login |

Vanguard Therapeutics Inc

Vanguard Therapeutics Inc

Profile last edited on: 1/31/2018
108 Eagle Trace Drive
Half Moon Bay, CA 94019
  (415) 203-0436
Business Identifier: Oral cell adhesion blocking agent: long-term prophylactic therapy for sickle cell disease patients.
Public Profile:
Vanguard Therapeutics, Inc. is an early stage firm developing an orally absorbable cell adhesion-blocking drug for the prophylactic therapy of sickle cell disease. Founded by long-term UCSF facultoy with important pharmaceutical industry experience, program is based on the knowledge that clinical problems of sickle cell disease are the result of abnormal blood flow and that adhesion of sickle red blood cells to the vascular endothelium is fundamental to the abnormal blood flow. P-selectin on vascular endothelial cells is central to sickle red blood cell adhesion, and the firm's compound effectively blocks P-selectin. Firm is addressing development of reliable assays for parent compound and the identification of a superior fraction of that compound for use as an active pharmaceutical ingredient in commercial development. Firm has associate status with JLabs

 Synopsis: Awardee Business Condition
Year Founded First SBIR Year Date of Last Award
Employee Range VC funded? IP Holdings
Revenue Range Private/Public Exchange/Symbol :

Unlock access

To unlock access to all SBIR-STTR company Profiles, a FREE site registration is required. Click here to register or login if you already have an account

Smart Office Options

SBIR firms in the news


Is this YOUR Company?

Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached

Do you know about this Awardees?

Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Contact information

Innovation Development Institute, LLC

   45 Beach Bluff Avenue, Suite 300
     Swampscott,  MA 01907-1542

  Tel:  (781) 595-2920